LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.25 -2.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.24

Max

1.28

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-34M 68M
Eelmine avamishind	3.59
Eelmine sulgemishind	1.25

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. veebr 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22. veebr 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22. veebr 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22. veebr 2026, 23:21 UTC

Tulu

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22. veebr 2026, 23:20 UTC

Tulu

Nickel Industries 2025 Operating Profit US$126.4 Million

22. veebr 2026, 23:19 UTC

Tulu

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22. veebr 2026, 23:19 UTC

Tulu

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22. veebr 2026, 23:18 UTC

Tulu

Nickel Industries Won't Pay a Final Dividend

22. veebr 2026, 23:16 UTC

Tulu

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22. veebr 2026, 21:35 UTC

Tulu

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22. veebr 2026, 21:34 UTC

Tulu

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22. veebr 2026, 21:34 UTC

Tulu

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22. veebr 2026, 21:33 UTC

Tulu

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22. veebr 2026, 21:33 UTC

Tulu

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22. veebr 2026, 21:28 UTC

Tulu

Ampol Final Dividend A$0.60/Share

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Revenue A$31.37 Billion, Down 10%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21. veebr 2026, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. veebr 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. veebr 2026, 22:12 UTC

Tulu

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. veebr 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. veebr 2026, 21:23 UTC

Tulu

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. veebr 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. veebr 2026, 21:01 UTC

Omandamised, ülevõtmised, äriostud

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. veebr 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.